Donanemab,Aducanumab
eli lilly,Biogen
['aducanumab', 'trailblazer,alz,4']
via #aanam: topline results of the trailblazer-alz 4 trial show that more patients with #alzheimers who used #donanemab reached amyloid clearance than those using #aducanumab: #neurotwitter #dementia 
The official news source of the American Academy of Neurology, published by Wolters Kluwer.